Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • ACA Enrollment
  • Ebola
  • PFAS in Drinking Water
  • Drug-Related Driving Deaths
  • Black Maternal Health

WHAT'S NEW

  • ACA Enrollment
  • Ebola
  • PFAS in Drinking Water
  • Drug-Related Driving Deaths
  • Black Maternal Health

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Jun 23 2016

Full Issue

Drug Lobby Calls For Scrutiny Of Outside Group That Makes Drug Pricing Recommendations

The goal of the Institute of Clinical and Economic Review is to develop an independent pricing system. But a global pharmaceutical lobby questions its ties with insurers. In other news, Medicare Part D spending on compounded drugs jumps 600 percent and startup Blink Health says it helps patients obtain medications more cheaply.

The Hill: New Shots Fired In Drug Pricing War

The pharmaceutical industry is opening a new line of attack against health insurers in the escalating battle over drug prices. Global drug lobby the Biotechnology Innovation Organization (BIO) is accusing insurance companies of funneling cash into a little-known outside group that recommends its own drug prices with hopes of driving down overall costs. (Ferris, 6/22)

Stat: Medicare Part D Spending On Compounded Drugs Is Skyrocketing

As federal regulators try to crack down on compounding pharmacies over safety concerns, a new report finds that spending by the Medicare Part D program for these medicines rose more than 600 percent over the past decade. And federal auditors say the trend raises questions about whether the drugs, which are customized for specific patient needs, were medically necessary or dispensed appropriately. (Silverman, 6/22)

Fox News: Company Offers Patients Cheaper Way To Obtain Prescription Drugs

A New York startup company wants to make the process of obtaining prescription drugs easier and cheaper for patients across the nation— including those people who don’t have health insurance. Blink Health, founded by brothers Geoffrey and Matthew Chaiken, boasts savings of up to 95 percent on more than 15,000 different medications including Prilosec, Propecia and Xanax. (6/23)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
  • Thursday, May 14
  • Wednesday, May 13
  • Tuesday, May 12
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF